Profile data is unavailable for this security.

About the company

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

  • Revenue in CHF (TTM)47.73bn
  • Net income in CHF7.39bn
  • Incorporated1996
  • Employees121.60k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Bayer AG35.02bn3.25bn79.01bn99.82k25.652.1512.752.263.728.4140.1544.500.44511.523.58350,781.404.
Roche Holding Ltd.53.30bn8.63bn189.86bn93.73k21.927.1114.943.5610.0410.0461.9830.970.69452.055.81568,619.7011.5013.4417.0219.9370.5471.6416.5619.701.0931.630.395373.265.383.22-9.85-1.7411.862.46
Novartis AG47.73bn7.39bn204.24bn121.60k25.022.5615.504.283.123.1020.1430.470.3812.585.97392,514.005.906.477.148.0166.1866.6915.4916.210.9119--0.277779.061.52-2.7215.67-3.48-2.192.67
Data as of Mar 16 2018. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF

Institutional shareholders

13.72%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 28 Feb 201858.11m2.22%
Norges Bank Investment Managementas of 31 Dec 201653.08m2.03%
NETA Capital Croatia ddas of 31 Jan 201851.54m1.97%
UBS AG (Investment Management)as of 31 Jan 201842.24m1.61%
Capital Research & Management Co. (Global Investors)as of 31 Dec 201737.48m1.43%
BlackRock Fund Advisorsas of 07 Mar 201829.22m1.12%
Wellington Management Co. LLPas of 31 Jan 201828.76m1.10%
Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 201821.57m0.82%
Capital Research & Management Co. (World Investors)as of 31 Dec 201720.11m0.77%
Dodge & Coxas of 31 Dec 201716.79m0.64%
More ▼
Data from 31 Dec 2016 - 28 Feb 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.